Invest in conquering cancer

To date, the company has raised capital from strategic investors. We are now seeking to raise additional funds to progress the clinical development of our lead candidate.

Interested in Investing?

If you are an Accredited Investor and are interested in learning more about investment opportunities with Soricimed Biopharma, please contact us.

Soricimed Biopharma Inc. is a private clinical stage oncology company developing first-in-class therapeutics against a novel cancer target.

First in class

Phase 1a

Targeted Peptide

17 patents

Orphan Drug Designation

Orphan Drug Designation

FDA orphan drug status for ovarian and pancreatic cancer.

Broad Patent Protection

Broad Patent Protection

Broad international patent protection including composition of matter and method claims.

Efficient Business Model

Efficient Business Model

Semi-virtual business model resulting in extremely capital efficient operation.


We are seeking additional capital to continue our clinical development of SOR-C13 and advance our Peptide-Drug Conjugate program.

To date, we have been financed by high net worth individuals and angel investors.

If you would like to learn more about the investment potential of Soricimed Biopharma Inc., please fill out the form at the top of the page.

Sign up to receive updates from Soricimed

Powered by Innovasium